1. CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study 
Thomas O. Bergmeijer, MD, Paul W.A. Janssen, MD, Jurjan C. Schipper, MD, Khalid Qaderdan, MD, Maycel Ishak, MD, Rianne S. Ruitenbeek, BSc, Folkert W. Asselbergs, MD, PhD, FESC, Arnoud W.J. van ‘t Hof, MD, PhD, Willem J.M. Dewilde, MD, Fabrizio Spanó, MD, Jean-Paul R. Herrman, MD, PhD, Johannes C. Kelder, MD, PhD, Maarten J. Postma, PharmD, PhD, Anthonius de Boer, MD, PhD, Vera H.M. Deneer, PharmD, PhD, Jurriën M. ten Berg, MD, PhD, FESC, FACC 
American Heart Journal 
Volume 168, Issue 1, Pages e1 (July 2014)
DOI: /j.ahj
Copyright © 2014 Mosby, Inc. Terms and Conditions

2. Figure
Flowchart.
American Heart Journal  , e1DOI: ( /j.ahj )
Copyright © 2014 Mosby, Inc. Terms and Conditions